Please select an option below to help us tailor your newsletter to best suit your content interests!
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Primary- OS: Secondary- TTP, PFS, ORR, DCR, DoR, PK, QoL